Income statement
USD
Annual
| Metric | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|
| Revenue | 5M | 7M | 10M | 7M | 9M |
| Gross Profit | 3M | 5M | 7M | 4M | 6M |
| Operating Income | -2M | -3M | -4M | -6M | -6M |
| EBITDA | -2M | -2M | -3M | -10M | -5M |
| Net Income | -3M | -4M | -9M | -10M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
-90.00%
Window
Jun 23, 2025 → Jun 5, 2026
Coverage: 241 bars · Jun 23, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Targeted Medical Pharma, Inc. (TRGM) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 90.0% across the available one-year price window (Jun 23, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of -26.0%, EPS growth of +26.7%, a dividend yield of 0.0%. What stands out right now is revenue -26.0%, EPS +26.7%, free cash flow -263.9% with operating margin -38.6% and ROIC 26.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TRGM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRGM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TRGM Max Drawdown
-90.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TRGM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$8.8M
+20.7% YoY
FY Net Income
-$4.2M
+56.4% YoY
Free Cash Flow
-$3.1M
-16.1% YoY
Revenue Growth
-26.0%
EPS Growth
+26.7%
Gross Margin
60.2%
Net Margin
-57.9%
Income statement
USD
| Metric | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|
| Revenue | 5M | 7M | 10M | 7M | 9M |
| Gross Profit | 3M | 5M | 7M | 4M | 6M |
| Operating Income | -2M | -3M | -4M | -6M | -6M |
| EBITDA | -2M | -2M | -3M | -10M | -5M |
| Net Income | -3M | -4M | -9M | -10M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|
| Cash & Equivalents | 83K | 12K | 492K | 327K | 147K |
| Total Assets | 2M | 3M | 5M | 11M | 9M |
| Total Liabilities | 15M | 12M | 12M | 13M | 8M |
| Shareholder Equity | -13M | -10M | -7M | -2M | 607K |
| Total Debt | 5M | 4M | 5M | 5M | 0 |
| Net Debt | 5M | 4M | 4M | 5M | -147K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
-8.9% YoY
Capital Expenditures
512K
-73.8% YoY
Free Cash Flow
3M
-16.1% YoY
Key ratios
Gross Margin
60.2%
Operating Margin
-38.6%
Net Margin
-57.9%
ROE
26.6%
Debt / Equity
-0.41x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.